Skip to main content

Table 1 Cox proportional hazards regression for RFS

From: Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective study

 

Whole cohort (a)

DM subgroup (b)

Univariate

Multivariate

Univariate

 

HR

95.0% CI

P

HR

95.0% CI

P

HR

95.0% CI

P

Age

0.86

0.59

1.25

0.415

     

0.94

0.84

1.06

0.306

Sex

1.94

1.14

3.30

0.014*

1.66

0.71

3.88

0.245

4.13

0.98

17.44

0.054

Smoking

1.34

0.91

1.96

0.136

0.84

0.46

1.52

0.558

3.438

0.311

38.06

0.314

BMI > 24 kg/m2

1.1

0.75

1.62

0.610

     

1.61

0.65

3.98

0.301

Hypertension

0.74

0.51

1.08

0.113

1.12

0.60

2.06

0.726

0.67

0.25

1.77

0.418

Cre > 1.5 mg/dL

1.03

0.60

1.77

0.921

     

1.04

0.42

2.56

0.936

Dialysis

0.88

0.28

2.78

0.831

     

1.57

0.21

11.7

0.658

History of other cancers

0.71

0.36

1.41

0.335

     

0.63

0.15

2.69

0.536

cT1

2.14

1.47

3.12

< 0.001*

2.05

1.06

3.97

0.034*

1.83

0.87

3.86

0.112

CIS

1.58

1.03

2.41

0.036*

0.69

0.34

1.39

0.297

1.34

0.6

2.96

0.476

High grade

1.72

1.14

2.58

0.010*

0.85

0.43

1.68

0.643

1.45

0.61

3.42

0.400

Tumor number ≥ 3

2.49

1.58

3.94

< 0.001*

3.46

1.90

6.33

< 0.001*

0.99

0.41

2.41

0.982

Tumor size ≥3 cm

1.94

1.12

3.36

0.018*

1.90

1.05

3.42

0.033*

1.94

0.64

5.83

0.239

Intravesical therapy

0.97

0.36

2.64

0.958

     

21.8

< 0.01

>  11.00

0.790

DM

1.3

0.85

2.00

0.229

1.11

0.57

2.19

0.755

     

Urine sugar ≥100

          

1.86

0.87

3.97

0.108

HbA1c ≥7

          

3.64

1.14

11.65

0.029*

Metformin

          

1.36

0.60

3.10

0.460

TZD

          

0.26

0.04

1.90

0.184

  1. a. Whole cohort: Male sex, T1 stage, CIS, high grade, tumor number ≥ 3, and tumor size ≥3 were associated with higher recurrence in univariate analysis. T1 stage, tumor number ≥ 3, and tumor size ≥3 were independent risk factors for recurrence in multivariate analysis
  2. b. DM subgroup: HbA1c ≥7 was associated with higher risk of recurrence
  3. CI confidence interval, CIS carcinoma in situ, DM diabetes mellitus; HR hazard ratio, RFS recurrence-free survival, TZDs thiazolidinedione; * P < 0.05